---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016251"
form_type: "8-K"
ticker: "TNGX"
cik: "0001819133"
company_name: "Tango Therapeutics, Inc."
filed_at: "2022-08-10T23:59:59+00:00"
generated_at: "2026-06-24T01:32:19.894269+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tango Therapeutics Q2 2022 net loss $24.9M; TNG908 Orphan Drug Designation

## Summary
- Cash, cash equivalents and marketable securities $416.4M as of June 30, 2022.
- Net loss $24.9M ($0.28/share) vs $4.5M ($0.09) in Q2 2021; R&D expense $23.7M vs $19.1M.
- TNG908 Phase 1/2 enrolling MTAP-deleted solid tumors; FDA Orphan Drug Designation for MPNST.
- TNG462 (45-fold more potent PRMT5 inhibitor) and TNG260 declared development candidates; IND filings expected 1H 2023.
- Added to Russell 2000, 3000 and Microcap indexes in June 2022.

## SEC filing metadata
- accession: 0000950170-22-016251
- form_type: 8-K
- ticker: TNGX
- cik: 0001819133
- company_name: Tango Therapeutics, Inc.
- filed_at: 2022-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819133/000095017022016251/0000950170-22-016251-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819133/000095017022016251/tngx-20220810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016251
- JSON: https://secwatch.observer/filing/0000950170-22-016251.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016251.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.